Lymphoma, Non-Hodgkin 
Welcome,         Profile    Billing    Logout  

9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lymphoma, Non-Hodgkin
NCT00981760: Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplantation

Recruiting
2/3
20
US
Total Body Irradiation, TBI, Fludarabine, Recipient Leukocyte Infusion, RLI
Massachusetts General Hospital
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma
06/10
06/10
NCT01595048 / 2010-019224-31: Combination Chemotherapy With or Without Rituximab in Treating Younger Patients With Stage III-IV Non-Hodgkin Lymphoma or B-Cell Acute Leukemia

Active, not recruiting
2/3
640
US, Canada, RoW
Rituximab, MOAB IDEC-C2B8, Prednisone, Etoposide, Lastet, Doxorubicin Hydrochloride, Cytarabine, CHX-3311, U-19920, Vincristine Sulfate, Kyocristine, Oncovin, VCR, Vincasar, Cyclophosphamide, Methotrexate, Methylprednisolone, MePRDL, Leucovorin Calcium, CF, Therapeutic Hydrocortisone, Aeroseb-HC, Cetacort, HC, Laboratory Biomarker Analysis
Children's Oncology Group, National Cancer Institute (NCI)
Childhood B Acute Lymphoblastic Leukemia, Childhood Burkitt Leukemia, Childhood Diffuse Large Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma
12/20
12/20
NCT00066300: Allogeneic Peripheral Stem Cell Transplantation Followed By Donor Lymphocyte Infusions in Treating Patients With Hematologic Cancer

Active, not recruiting
2
US
graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclophosphamide, cyclosporine, fludarabine phosphate, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
National Heart, Lung, and Blood Institute (NHLBI)
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
 
 
NCT02259556: CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas

Recruiting
1/2
30
RoW
CART30, anti-CD30 CAR T cells
Chinese PLA General Hospital
Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
10/18
10/29
NCT00445666: Tumor-Infiltrating Lymphocytes in Treating Patients With Persistent or Recurrent B-Cell Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma After a Previous Donor Stem Cell Transplant

Active, not recruiting
1
36
US
graft-versus-tumor induction therapy, therapeutic tumor infiltrating lymphocytes, cytogenetic analysis, fluorescence in situ hybridization, microarray analysis, polymerase chain reaction, flow cytometry, immunoenzyme technique, immunohistochemistry staining method, immunologic technique, laboratory biomarker analysis, biopsy, conventional surgery
National Cancer Institute (NCI)
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
 
 
NCT00810966: ABT-888 and Cyclophosphamide in Treating Patients With Solid Tumors or Lymphoma That Did Not Respond to Previous Therapy

Active, not recruiting
1
50
US
cyclophosphamide, veliparib, immunologic technique, laboratory biomarker analysis, liquid chromatography, mass spectrometry, pharmacological study
National Cancer Institute (NCI)
Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
 
 
NCT00423826: Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

No Longer Available
N/A
US
Busulfan, Busulfex®, Myleran®, Cytarabine, DepoCyt(TM), Liposomal Ara-C, Fludarabine phosphate, Fludara, mycophenolate mofetil, Cellcept, tacrolimus, Advagraf, Prograf, Protopic, allogeneic hematopoietic stem cell transplantation, umbilical cord blood transplantation, total-body irradiation
Barbara Ann Karmanos Cancer Institute, National Cancer Institute (NCI)
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Secondary Myelofibrosis
01/15
01/15
EAP, NCT00720603: This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.

No Longer Available
N/A
US
Plerixafor, AMD3100, Mozobil
Genzyme, a Sanofi Company
Non-Hodgkin's Lymphoma, Hodgkin's Disease, Multiple Myeloma
 
 
NCT02066883: Prognostic Potential Cell Surface Markers CD47 / CD27 / CD8 and Pim-kinase in Patients With Hematologic Malignancies or Solid Tumors

Recruiting
N/A
150
RoW
Cancer Centre of Monoclonal Therapy, LLC
Solid Tumor, Ovarian Cancer, Non-small Cell Lung Cancer, Chronic Lymphocytic Leukemia, Burkitt's Lymphoma
07/15
02/17

Download Options